Pacira BioSciences, Inc.
NASDAQPCRX heads into its May 1 earnings print with a notable divergence: short sellers are retreating while company insiders are cashing out. The short-side picture has shifted meaningfully heading into the release. Short interest has fallen roughly 9% over the past week and 15% over the past month, bringing it to 17.1% of the free float — still elevated in absolute terms, but the…
Snapshot as of 7 May 2026
PCRX heads into its May 1 earnings print with a notable divergence: short sellers are retreating while company insiders are cashing out. The short-side picture has shifted meaningfully heading into the release. Short…
Pacira BioSciences heads into its Q1 2026 earnings release — due after the close today — with two colliding stories: a meaningful short-covering wave over the past week, and an active proxy battle with a dissident…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for PCRX — free to start on ORTEX.
Sign up for free →Open PCRX on ORTEX